Much larger Phase III trial planned for Moderna vaccine

27 July 2020
moderna_therapeutics_large

mRNA therapeutics and vaccines specialist Moderna Therapeutics (Nasdaq: MRNA) has secured an additional $472 million from the US authorities for late-stage development of mRNA-1273.

The money from the Biomedical Advanced Research and Development Authority (BARDA) builds on an earlier, similarly-sized commitment, for development of the COVID-19 vaccine candidate.

While a smaller trial was originally planned, Moderna changed course after consulting with the US regulator over the past several months.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology